Benjamien Moeyaert (left), Lolita Petit (centre), and Els Henckaerts (right)
“The convergence of capsid engineering, conjugation chemistry, and ligand design is opening new avenues for truly targeted gene delivery.”
The maturation of AAV-based gene therapy has intensified demand for vectors with both high potency and precise, cell-specific delivery, yet traditional capsid engineering approaches remain limited by manufacturability, translational gaps, and slow development. Emerging post-manufacture conjugation platforms, enabled by advanced chemical and enzymatic strategies, offer a modular alternative by attaching targeting ligands to purified AAV capsids, improving flexibility, scalability, and translational relevance.
